Home LiteratureArticle Details
PMID: 7513677 Published · ppublish English Journal Article

Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors.

Hepatology (Baltimore, Md.) ·Vol. 19 ·No. 5 ·1994-05-00 ·Pages 1115-23

Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, Alberti A, Idèo G

Abstract

A total of 84 patients with hepatocellular carcinoma and cirrhosis were analyzed retrospectively to investigate prognostic factors. All patients received transarterial oily chemoembolization as the only anticancer therapy. The follow-up range was 1 to 39 mo (median, 9.5 mo). The overall actuarial survival rates at 12, 24 and 30 mo were 62%, 31% and 24%, respectively. According to univariate analysis, variables significantly associated with survival were age, Child-Pugh grade, total serum bilirubin, Okuda stage, tumor size, degree of labeling of the tumor with Lipiodol, gelatin foam use, changes with treatment in tumor size and changes with treatment in alpha-fetoprotein concentration. Two multivariate analyses were performed. When pretreatment and treatment variables were considered, parameters with independent prognostic value were age, Child-Pugh grade, total serum bilirubin, tumor size and degree of Lipiodol labeling of the tumor. When follow-up variables were also considered, we (a) confirmed the prognostic significance of all these parameters (age, Child-Pugh grade, total serum bilirubin, tumor size) and (b) found the independent prognostic value of the change in tumor size (or change in alpha-fetoprotein concentration). Both models yielded different risk coefficients for each class of each variable. Two simple prognostic indexes, based on these coefficients, are proposed: an "initial" index (including pretreatment and treatment variables) and a "follow-up" index (also including follow-up variables). According to the two indexes, the patients were classified into three groups with different prognoses: good (93% and 100% actuarial survival at 1 yr for the initial and follow-up indexes, respectively), intermediate (65% and 53%, respectively) and poor (27% for both indexes).

MeSH Terms
Actuarial Analysis Adult Age Factors Aged Bilirubin/blood Carcinoma, Hepatocellular/mortality,pathology,therapy Chemoembolization, Therapeutic/methods Doxorubicin/administration & dosage Female Follow-Up Studies Gelatin Sponge, Absorbable/administration & dosage Hepatic Artery Humans Iodized Oil/administration & dosage Liver Neoplasms/mortality,pathology,therapy Male Middle Aged Multivariate Analysis Prognosis Retrospective Studies Survival Rate alpha-Fetoproteins/analysis
Chemicals
alpha-Fetoproteins Iodized Oil Doxorubicin Bilirubin
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Mondazzi L
Crespi Division of Medicine, Niguarda Cà Granda Hospital, Milan, Italy.
Bottelli R
Brambilla G
Rampoldi A
Rezakovic I
Zavaglia C
Alberti A
Idèo G
Article Info
Journal
Hepatology (Baltimore, Md.)
Abbr.
Hepatology
ISSN
0270-9139
Published
1994-05-00
Pages
1115-23
Language
English
Region
United States
NLM ID
8302946
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com